NCT03903094View on ClinicalTrials.gov

A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden

CompletedOBSERVATIONAL

Enrollment

6,295,279

Participants

Timeline

Start Date

March 7, 2019

Primary Completion Date

May 6, 2022

Study Completion Date

May 6, 2022

Conditions

Overactive Bladder (OAB)

Interventions

OTHER

Non-Interventional

Overview of anticholinergic burden, rather than to evaluate specific drugs

Trial Locations (2)

Unknown

Site AU61001, Melbourne

Site KR82001, Seoul

All Listed Sponsors

lead

Astellas Pharma Singapore Pte. Ltd.

INDUSTRY

NCT03903094 - A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden | Biotech Hunter | Biotech Hunter